Replies to post #521272 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Not necessarily because if they are just grabbagging different immune cells and putting them through the same processing I don’t think they would be required to filter out the dendritic cells because NWBO holds a patent. Now if they were deliberately trying to get more dendritic cells than others because they knew it was the active ingredient or using the same processing for all cells that NWBO used for dendritic then it would be an issue.

Probably this sneaky end run around the parents would be allowed but the formula would be less efficacious.

Either way it’s time to get DCVax-L to market not to mention Direct.

[exwannabe]

So this is DCVAX weasel-worded to sound like something different.
I would think NWBO patents would prevent them from doing this or require them to pay a hefty licensing fee if NWBO decided to license it.

They might also try a patent suit against every vaccine ever produced because they all work by activating DCs in the body.

NWBO's patents are not sufficient to prevent actual DC vaccines from being marketed. They certainly are not going to prevent a viral encapsulated mRNA core from being marketed.